Ryaltris

Symptomatic treatment of moderate to severe seasonal allergic rhinitis & associated ocular symptoms in adults, adolescents & childn ≥6 yr.

Adult & adolescent ≥12 yr 2 sprays in each nostril bid. Childn 6-11 yr 1 spray in each nostril bid.

Hypersensitivity. Severe nasal infection, especially candidiasis. Haemorrhagic diathesis or history of recurrent nasal bleeding.

Discontinue treatment if hypersensitivity reactions occur; localized nasal or pharyngeal fungal infection develops; persistent nasopharyngeal irritation occurs. Not to be used in the presence of untreated localised infection involving the nasal mucosa. Avoid use in patients w/ recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred; spraying into the eyes or mouth. Reports of nasal ulceration, nasal septal perforation & epistaxis. Patients w/ active or quiescent resp TB infection; untreated fungal, bacterial, systemic viral or parasitic infections, or ocular herpes simplex. Periodically examine patients using Ryaltris over several mth or longer for possible changes in nasal mucosa. Consider referral to an ophthalmologist if patient presents w/ blurred vision or other visual disturbances. Risk for hypercorticism & adrenal suppression when used at higher than recommended dosages or in susceptible individuals at recommended dosages. Caution when transferring from systemic steroids to Ryaltris in patients w/ possible adrenal impairment. May experience symptoms of w/drawal eg, joint &/or muscular pain, lassitude, & depression, initially during transfer from systemic corticosteroid; may unmask pre-existing allergic conditions eg, allergic conjunctivitis & eczema. Concomitant use w/ alcohol or other CNS depressants. May affect ability to drive & use machines. Pregnancy & lactation. Childn <6 yr; monitor growth velocity reduction in paed patients.

Dysgeusia; headache. Adult & adolescent ≥12 yr: Epistaxis, nasal discomfort; URTI, UTI, viral URTI; cough, bronchitis; back pain; nausea; procedural pain.

Increased plasma conc & increased risk of systemic side effects w/ strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat-containing products).

Nasal Decongestants & Other Nasal Preparations

R01 - NASAL PREPARATIONS ; Used in nasal preparations.

S